Trial for new breast cancer prevention pill halted early
NCT ID NCT05128773
Summary
This study aimed to see if a new drug called amcenestrant was better than the standard drug tamoxifen at keeping early-stage, hormone-sensitive breast cancer from coming back. It was for patients who had to stop their initial hormone therapy due to side effects. The trial was designed to last up to 10 years per person but was terminated very early, after only 3 people enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1521622
Santiago, Reg Metropolitana de Santiago, Chile
-
Investigational Site Number :1561599
Haikou, 570311, China
Conditions
Explore the condition pages connected to this study.